CAM
ITOS

Cormorant Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Cormorant Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$3.22M – 84
2022
Q1 		$3.22M Sell
100,000
-50,000
-33% -$1.82M 0.25% 56
2021
Q4 		$6.98M Sell
150,000
-138,330
-48% -$4.6M 0.42% 49
2021
Q3 		$7.79M Hold
288,330
– – 0.32% 60
2021
Q2 		$7.4M Sell
288,330
-11,670
-4% -$278K 0.25% 71
2021
Q1 		$10.3M Hold
300,000
– – 0.23% 72
2020
Q4 		$10.1M Sell
300,000
-50,000
-14% -$1.32M 0.24% 64
2020
Q3 		$8.63M Buy
+350,000
New +$9.41M 0.33% 63

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cormorant Asset Management's ITOS Position: Q2 2022 in Review

Cormorant Asset Management sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 100,000 shares — an estimated $3.22M sold.

Cormorant Asset Management first reported a position in ITOS in Q3 2020 and held it in 7 quarters. The position peaked at $10.3M in Q1 2021. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • Cormorant Asset Management reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Cormorant Asset Management sold 100,000 iTeos Therapeutics shares in Q2 2022, an estimated $3.22M.
  • Cormorant Asset Management first reported a position in iTeos Therapeutics in Q3 2020 and held it in 7 quarters.
  • Cormorant Asset Management's iTeos Therapeutics position peaked at $10.3M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Cormorant Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.